ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis

Author:

Chiu Kuo-Liang123,Lin Yu-Sen14,Kuo Ting-Ting5,Lo Chia-Chien5,Huang Yu-Kai5,Chang Hsien-Fang6,Chuang Eric Y.6,Lin Ching-Chan17,Cheng Wei-Chung89,Liu Yen-Nien10,Lai Liang-Chuan611,Sher Yuh-Pyng185

Affiliation:

1. Graduate Institute of Clinical Medical Science, China Medical University, Taichung 404, Taiwan

2. Division of Chest Medicine, Department of Internal Medicine, Taichung Tzu-Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung 427, Taiwan

3. School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 970, Taiwan

4. Division of Thoracic Surgery, China Medical University Hospital, Taichung 404, Taiwan

5. Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan

6. Bioinformatics and Biostatistics Core, Center of Genomic Medicine, National Taiwan University, Taipei 100, Taiwan

7. Division of Hematology and Oncology, China Medical University Hospital, Taichung 404, Taiwan

8. Graduate Institute of BioMedical Sciences, China Medical University, Taichung 404, Taiwan

9. Research Center for Tumor Medical Science, China Medical University, Taichung 404, Taiwan

10. Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan

11. Graduate Institute of Physiology, National Taiwan University, Taipei 106, Taiwan

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3